Why You Should Consider Keeping BDX Stock in Your Current Portfolio

Becton, Dickinson and Company: Well-Positioned for Growth in the Coming Quarters

BDX, also known as BD, is poised for growth in the coming quarters due to its solid product portfolio. The optimism stems from a strong fourth-quarter fiscal 2024 performance and several strategic deals that are expected to contribute further.

However, macroeconomic concerns and stiff competition persist, which may offset some of the gains. Despite this, the company’s robust product launches and strategic deals make it an attractive investment opportunity.

Past Performance

Over the past year, BDX has lost 6.9% against the industry’s 0.3% rise and the S&P 500’s 26% growth. The company has a market capitalization of $66.26 billion and projects 9.6% growth for the next five years.

BDX’s earnings have surpassed estimates in all four trailing quarters, with an average surprise of 6.5%. This performance suggests that the company is well-positioned to maintain its strong performance in the coming quarters.

Factors Favoring BDX’s Growth

Robust Product Launches

BD has recently introduced several innovative products, signaling strong momentum in its portfolio expansion. Some notable launches include:

• BD Intraosseous Vascular Access System: This system enables rapid delivery of fluids or medication in critical emergencies.
• BD OMICS-One XT Library Preparation Reagent Kits: These kits are part of a series developed in collaboration with Hamilton, featuring the BD OMICS-One XT WTA Assay and the Hamilton Microlab NGS STAR automated liquid handling platform.
• BD Neopak XtraFlow Glass Prefillable Syringe: This syringe is designed to address the increasing demand for biologic therapies.

The company has announced plans for more than 25 new product launches in fiscal 2025, including the next-generation Pyxis platform. This advanced system will leverage BD’s AI platform to integrate data across its smart devices, ensuring a seamless user experience.

Strategic Deals

BD has made significant progress in inking strategic deals over the past few months. Some notable agreements include:

• Acquisition of Edwards Lifesciences’ Critical Care product group: This acquisition will be renamed BD Advanced Patient Monitoring.
• Global collaboration agreement with Quest Diagnostics: This partnership aims to develop, manufacture, and commercialize flow cytometry-based companion diagnostics.

Strong Q4 Results

BD exited the fourth quarter of fiscal 2024 with better-than-expected results. Solid top-line results, along with improvements in organic revenues and bottom-line performances, were impressive. Robust performances by all segments and both geographic regions were encouraging.

Factors That May Offset the Gains for BDX

Macroeconomic Concerns

Global economic challenges, including rising inflation and volatile capital markets, pose risks to the demand and pricing of BD’s products and services. These conditions can disrupt its supply chain, impact production, and increase borrowing costs, affecting its business.

Stiff Competition

BD operates in an increasingly complex and challenging medical technology marketplace. Although technological advances and scientific discoveries have accelerated the pace of change in medical technology, the regulatory environment of medical products is becoming more complex and vigorous. Acquisitions and collaborations by and among companies seeking a competitive advantage also affect the competitive environment.

Estimate Trend

BD is witnessing a positive estimate revision trend for fiscal 2025. The Zacks Consensus Estimate for its earnings has increased in recent months, suggesting that analysts expect the company to maintain its strong performance.

Comparable Stocks

Some comparable stocks to BDX include:

• Abbott Laboratories (ABT): This company has an estimated earnings growth rate of 10% for 2025 and delivered a trailing four-quarter average earnings surprise of 1.64%.
• Accuray Incorporated (ARAY): This company has an estimated earnings growth rate of 1200% for 2025, but its earnings have missed estimates in three of the trailing four quarters.
• Masimo Corporation (MASI): This company has an estimated earnings growth rate of 14.4% for 2025 and delivered a trailing four-quarter average earnings surprise of 17.10%.

These stocks offer similar investment opportunities to BDX, but with different growth rates and performance histories.

Conclusion

BDX is well-positioned for growth in the coming quarters due to its robust product launches and strategic deals. However, macroeconomic concerns and stiff competition may offset some of the gains. As with any investment opportunity, it’s essential to conduct thorough research and consider multiple factors before making a decision.

Want the latest recommendations from Zacks Investment Research?

Today, you can download 7 Best Stocks for the Next 30 Days. Click here to get this free report.

Abbott Laboratories (ABT) : Free Stock Analysis Report
Accuray Incorporated (ARAY) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

View Comments